The future of endometrial cancer diagnosis is here. The WID-easy test is not just a new tool; it is a smarter, kinder, and more efficient standard of gynaecological care. We offer this simple, rapid and accurate swab test to detect endometrial cancers, including the ones missed by transvaginal scans.
For too long, the diagnostic pathway for endometrial cancer in women presenting with abnormal uterine bleeding (AUB) has relied on methods that are invasive, subjective, and place a significant burden on our healthcare systems.
The WID-easy test is a rapid, more sustainable, patient-friendly, and highly accurate molecular test that detects endometrial cancer through a simple cervico-vaginal swab. By analysing the DNA methylation status of specific biomarkers (GYPC & ZSCAN12), it provides an objective and non-invasive method to effectively triage patients, marking a monumental step forward in women’s health.
The clinical evidence is compelling and robust which has been validated in international studies, including NHS patient cohorts. The WID-easy test demonstrates outstanding performance with ~96.5% Sensitivity and >99% Negative Predictive Value (NPV). It generates over 90% fewer false positives compared to transvaginal ultrasound (TVUS), without missing additional cancers. This innovation is meant to enhance patient experience and build a more sustainable, modern healthcare service in gynaecology.
